Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights
Open Access
- 19 January 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (1), 125
- https://doi.org/10.3390/biom11010125
Abstract
Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling pathways that are key drivers of BC aggressiveness. Methods: In the present review, the interaction between BC, host metabolism, and patients’ prognosis has been reviewed across available literature evidence. Conclusions: Obesity, metabolic syndrome, and insulin resistance are all involved in BC growth and could have a relevant impact on prognosis. All these factors act through a pro-inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher risk of BC development and worse prognosis.This publication has 65 references indexed in Scilit:
- Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical TrialJournal of Clinical Oncology, 2012
- Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast CancerJournal of Clinical Oncology, 2011
- Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium StudiesJNCI Journal of the National Cancer Institute, 2010
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- A Case-Control Study of Body Mass Index and Breast Cancer Risk in White and African-American WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- Metformin: A Therapeutic Opportunity in Breast CancerClinical Cancer Research, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Is it Time to Test Metformin in Breast Cancer Clinical Trials?Cancer Epidemiology, Biomarkers & Prevention, 2009
- Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal WomenJNCI Journal of the National Cancer Institute, 2008
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007